evotaz 300mg150mg tablets
bristol-myers squibb pharmaceuticals ltd - atazanavir sulfate; cobicistat - tablet - 300mg ; 150mg
empliciti 400mg powder for concentrate for solution for infusion vials
bristol-myers squibb pharmaceuticals ltd - elotuzumab - powder for solution for infusion - 400mg
empliciti 300mg powder for concentrate for solution for infusion vials
bristol-myers squibb pharmaceuticals ltd - elotuzumab - powder for solution for infusion - 300mg
daklinza 90mg tablets
bristol-myers squibb pharmaceuticals ltd - daclatasvir dihydrochloride - tablet - 90mg
nivolumab bms
bristol-myers squibb pharma eeig - nivolumab - carcinoma, non-small-cell lung - antineoplastic and immunomodulating agents, monoclonal antibodies - nivolumab bms is indicated for the treatment of locally advanced or metastatic squamous non-small cell lung cancer (nsclc) after prior chemotherapy in adults.
sustiva 100mg capsules
bristol-myers squibb pharmaceuticals ltd - efavirenz - capsule - 100mg
sustiva 50mg capsules
bristol-myers squibb pharmaceuticals ltd - efavirenz - capsule - 50mg
sustiva 200mg capsules
bristol-myers squibb pharmaceuticals ltd - efavirenz - capsule - 200mg
sustiva 600mg tablets
bristol-myers squibb pharmaceuticals ltd - efavirenz - tablet - 600mg
zerit 20mg capsules
bristol-myers squibb pharmaceuticals ltd - stavudine - capsule - 20mg